Sputnik V ( sputnik vaccine )
Sputnik V ( sputnik vaccine ) GENERAL INFORMATION S putnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is already registered in more than 65 countries. The ongoing Sputnik V post-registration clinical trial in Russia involved more than 31,000 volunteers. Phase 3 clinical trials of Sputnik V have been conducting in the UAE, India, Venezuela and Belarus. Sputnik V is one of the three vaccines in the world with efficacy of over 90%. The Vaccine’s efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases. According to analysis of data from 3.8 million vaccinated persons in Russia Sputnik V demonstrates 97.6% efficacy. RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for internat...